Table 1.
Characteristics of Real-World Studies of Outpatient Treatment for Deep Vein Thrombosis.
| Author, Year (N) | Country | Study Type | Data Source | Timing of Sample | Male, n (%) | Age, Mean ± SD | Primary Anticoagulant Upon Discharge |
|---|---|---|---|---|---|---|---|
| Chu, 2017 (N = 69) | US | R, clinical | Single-center EHR | 2015-2016 | NR | 53 ± 17 | DOAC |
| Douce, 2017 (N = 141) | US | P, clinical | REGARDS | 2003-2011 | 75 (53) | 67 (median) | NR |
| Kabrhel, 2017 (N = 1112) | US | P, clinical | Multicenter EHR | 2015 | NR | NR | DOAC |
| Mansour, 2017 (N = 23 015) | Canada | R, claims | Alberta administrative databases | 2002-2012 | 10 313 (45) | 56.3 ± NR | NR |
| Mausbach, 2017 (N = 236) | Israel | R, clinical | Single-center EHR | 2013-2015 | 105 (44) | 68 (median) | LMWH and/or VKA |
| Tichter, 2017 (N = 690 000) | US | R, survey | NHAMCS | 2009-2013 | 275 172 (40) | NR | NR |
| Barrett, 2016 (N = 6) | US | P, clinical | Single-center EHR | 2016 | NR | NR | DOAC |
| Lamb, 2016 (N = 1 146 469) | US | R, claims | NEDS | 2006-2012 | NR | NR | NR |
| Singer, 2016 (N = 652 000) | US | R, survey | NHAMCS | 2006-2010 | 325 001 (50) | 58 ± NR | NR |
| Stein, 2016 (N = 2 671 452) | US | R, claims | NEDS/NIS | 2007-2012 | 1 246 129 (47) | NR | NR |
| Beam, 2015 (N = 71) | US | P, clinical | Multicenter EHR | 2013-2014 | NR | 47 ± 16 | DOAC |
| Dentali, 2015 (N = 1452) | Italy | P, clinical | RIETE | 2006-2013 | 753 (52) | 60 ± 18 | LMWH and/or VKA |
| Padron, 2015 (N = 9)a | US | P, clinical | Single-center EHR | 2012-2013 | NR | NR | LMWH and/or VKA |
| Rosa-Salazar, 2015b (N = 1135) | Internationalc | P, clinical | RIETE | 2001-2014 | 573 (51) | 52 ± 18 | LMWH and/or VKA |
| Stein, 2015 (N = 96) | US | R, clinical | Multicenter EHR | 2013-2014 | 43 (50) | 59 ± 16 | NR |
| Trujillo-Santos, 2015 (N = 15 280) | Internationalc | P, clinical | RIETE | 2001-2013 | 7892 (52) | 61 ± 17 | LMWH and/or VKA |
| Falconieri, 2014 (N = 7) | US | R, clinical | Single-center EHR | 2013-2014 | NR | NR | DOAC |
| Lozano, 2014 (N = 13 493) | Internationalc | P, clinical | RIETE | 2001-2012 | 7023 (52) | 62 ± 17 | LMWH and/or VKA |
| Misky, 2014 (N = 107) | US | P, clinical | Single-center EHR | 2011-2012 | NR | 52.4 ± NR | LMWH and/or VKA |
| Davis, 2013 (N = 14) | US | P, clinical | Single-center EHR | NR | NR | NR | LMWH and/or VKA |
| Gibson-Chambers, 2013 (N = 845 000) | US | R, claims | NEDS | 2006-2010 | 397 150 (47) | NR | NR |
Abbreviations: DOAC, direct oral anticoagulant; EHR, electronic health record; LMWH, low-molecular weight heparin; MASTER, Multicenter Advanced Study for a ThromboEmbolism Registry; NEDS, Nationwide Emergency Department Sample; NHAMCS, National Hospital Ambulatory Medical Care Survey; NIS, National Inpatient Sample; NR, not reported; P, prospective; R, retrospective; RIETE, Registro Informatizado de Enfermedad TromboEmbólica; REGARDS, Reasons for Geographic and Racial Differences in Stroke; SD, standard deviation; US, United States; VKA, vitamin K antagonist.
a Reported sample size included patients with both deep vein thrombosis and pulmonary embolism.
b All included patients had upper extremity deep vein thrombosis.
c Countries include Spain, France, Italy, Israel, Germany, Switzerland, Republic of Macedonia, and Brazil.